| Item Type | Name |
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
|
Academic Article
|
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
|
|
Academic Article
|
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
|
|
Academic Article
|
Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
|
|
Academic Article
|
Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
|
|
Academic Article
|
Controversies in treatment of AML: case-based discussion.
|
|
Academic Article
|
Progress in the treatment of adults with acute lymphoblastic leukemia.
|
|
Academic Article
|
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
|
|
Academic Article
|
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Clinical trials in adult AML.
|
|
Academic Article
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
|
|
Academic Article
|
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
|
|
Academic Article
|
Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
|
|
Academic Article
|
Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
|
|
Academic Article
|
Adult acute lymphoblastic leukemia: concepts and strategies.
|
|
Academic Article
|
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
|
|
Academic Article
|
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
|
|
Academic Article
|
Successful allogeneic transplantation of patients with suspected prior invasive mold infection.
|
|
Academic Article
|
BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants.
|
|
Academic Article
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
|
|
Academic Article
|
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
|
|
Academic Article
|
Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options.
|
|
Academic Article
|
T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse.
|
|
Academic Article
|
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
|
|
Academic Article
|
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).
|
|
Academic Article
|
Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.
|
|
Academic Article
|
Allogeneic and autologous transplantation for chronic lymphocytic leukemia.
|
|
Academic Article
|
Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.
|
|
Academic Article
|
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.
|
|
Academic Article
|
Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant.
|
|
Academic Article
|
Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.
|
|
Academic Article
|
Novel drug targets in acute leukemia.
|
|
Academic Article
|
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
|
|
Academic Article
|
Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment.
|
|
Academic Article
|
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
|
|
Academic Article
|
Stem cell transplantation eliminates alloantibody in a highly sensitized patient.
|
|
Academic Article
|
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
|
|
Academic Article
|
Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion.
|
|
Academic Article
|
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
|
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
|
Academic Article
|
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Management of acute lymphoblastic leukemia in young adults.
|
|
Academic Article
|
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
|
|
Academic Article
|
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
|
|
Academic Article
|
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.
|
|
Academic Article
|
Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
|
|
Academic Article
|
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.
|
|
Academic Article
|
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.
|
|
Academic Article
|
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation.
|
|
Academic Article
|
Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.
|
|
Academic Article
|
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
|
|
Academic Article
|
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.
|
|
Academic Article
|
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.
|
|
Academic Article
|
A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT.
|
|
Academic Article
|
A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
|
|
Academic Article
|
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation.
|